Health Care • Biotechnology: Pharmaceutical Preparations
$294.89 ▲ +4.10
(+1.41%)
MKT CAP: $513.86B • VOL: 6.90M
52W L $191 52W H $299
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$248
MEDIAN
$330
MEAN
$336
HIGH
$401
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ABBV TAPE
ABBV // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $356.82 | $339.12 | 2025-02-14 | $268.35 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $371.56 | $347.97 | 2025-02-06 | $277.20 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $336.17 | $324.38 | 2025-01-29 | $283.09 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $300.79 | — | 2025-01-17 | $288.99 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $259.50 | $280.15 | 2025-01-09 | $262.45 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $350.92 | $306.69 | 2024-12-18 | $256.55 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $286.04 | $297.84 | 2024-12-04 | $274.25 | -4.3% | 48% | C |